Guardant Health prelim Q4 revenue rises 39%, beats expectations

Guardant Health

12/01/2026 05:36

Overview

Precision oncology firm's preliminary Q4 revenue rises 39%, beating analyst expectations

Company reports 38% increase in oncology test volumes for Q4 2025

Outlook

Guardant Health expects continued growth in oncology with new product launches

Company anticipates Shield's expanded capabilities to enhance clinical value in 2026

Guardant Health did not provide specific financial guidance for future periods

Result Drivers

ONCOLOGY TEST VOLUME - Co reported a 38% increase in oncology test volumes, driven by innovations from the Smart Platform and commercial execution

SHIELD SCREENING GROWTH - Shield screening tests jumped from 6,400 to 38,000, bolstered by multi-cancer detection capabilities

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Beat
$280 mln
$267.82 mln (20 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 23 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Guardant Health Inc is $120.00, about 8.9% above its January 9 closing price of $110.17

Press Release: ID:nBw2V8VVda

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)